-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 24, 2021, Ionis pharmaceuticals announced that vupanorsen, jointly developed with Pfizer, has reached primary and critical secondary clinical endpoints in phase 2b clinical trials
Vupanorsen used Ionis' Ligand-Coupled Antisense (LICA) technology to target the reduction of the key regulatory factor ANGPTL3 protein level in the liver
In a phase 2a trial, vupanorsen significantly reduced triglyceride levels in patients with hyperlipidemia, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD)
This multicenter, double-blind, controlled Phase 2b trial enrolled 286 dyslipidemia subjects (≥40 years old), defined as non-HDL-C (≥100 mg/dL) and TG (150-500 mg/dL) ) Is elevated and is receiving a stable dose of statin therapy
In terms of safety, the most common adverse event in the trial was injection site reaction, which occurred most often in the highest dose group
Reference materials:
[1] Ionis announces that Pfizer reports topline results from Phase 2b clinical study of vupanorsen.
(The original text has been deleted)
